RedHill Biopharma Ltd.
RDHL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $8,043 | $6,530 | $61,800 | $85,757 |
| % Growth | 23.2% | -89.4% | -27.9% | – |
| Cost of Goods Sold | $3,192 | $3,459 | $33,337 | $49,406 |
| Gross Profit | $4,851 | $3,071 | $28,463 | $36,351 |
| % Margin | 60.3% | 47% | 46.1% | 42.4% |
| R&D Expenses | $1,588 | $3,528 | $7,279 | $29,498 |
| G&A Expenses | $14,515 | $28,880 | $54,970 | $76,603 |
| SG&A Expenses | $15,517 | $30,975 | $64,028 | $87,988 |
| Sales & Mktg Exp. | $1,002 | $2,095 | $9,058 | $11,385 |
| Other Operating Expenses | $2,359 | -$44,064 | $0 | $0 |
| Operating Expenses | $19,464 | -$9,561 | $71,307 | $117,486 |
| Operating Income | -$14,613 | $12,632 | -$42,844 | -$81,135 |
| % Margin | -181.7% | 193.4% | -69.3% | -94.6% |
| Other Income/Exp. Net | $6,345 | $11,284 | -$28,825 | -$16,609 |
| Pre-Tax Income | -$8,268 | $23,916 | -$71,669 | -$97,744 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,268 | $23,916 | -$71,669 | -$97,744 |
| % Margin | -102.8% | 366.2% | -116% | -114% |
| EPS | -7 | 46 | -600 | -1,000 |
| % Growth | -115.2% | 107.7% | 40% | – |
| EPS Diluted | -7 | 46 | -600 | -1,000 |
| Weighted Avg Shares Out | 2,465 | 518 | 124 | 93 |
| Weighted Avg Shares Out Dil | 2,465 | 518 | 124 | 93 |
| Supplemental Information | – | – | – | – |
| Interest Income | $133 | $94 | $140 | $51 |
| Interest Expense | $55 | $367 | $41,333 | $16,567 |
| Depreciation & Amortization | $619 | $1,990 | $8,154 | $18,149 |
| EBITDA | -$7,594 | $26,273 | -$22,182 | -$63,028 |
| % Margin | -94.4% | 402.3% | -35.9% | -73.5% |